Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. May 15, 2026; 18(5): 115681
Published online May 15, 2026. doi: 10.4251/wjgo.v18.i5.115681
Published online May 15, 2026. doi: 10.4251/wjgo.v18.i5.115681
Evolution of non-invasive colorectal neoplasm detection
Sun Jung Kim, Tae-Gyun Lee, Jin-Min Jung, Chang Woo Kim, Department of Surgery, Ajou University School of Medicine, Suwon 16499, South Korea
Sun Jung Kim, Graduate School of Medicine, Yonsei University College of Medicine, Seoul 03722, South Korea
Author contributions: Kim SJ drafted the manuscript; Lee TG, Jung JM, and Kim CW contributed to review and editing; Kim CW contributed to supervision of the study; all authors have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Chang Woo Kim, MD, PhD, Professor, Department of Surgery, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, South Korea. kcwgkim@gmail.com
Received: October 27, 2025
Revised: December 4, 2025
Accepted: January 30, 2026
Published online: May 15, 2026
Processing time: 202 Days and 1.3 Hours
Revised: December 4, 2025
Accepted: January 30, 2026
Published online: May 15, 2026
Processing time: 202 Days and 1.3 Hours
Core Tip
Core Tip: Non-invasive colorectal cancer (CRC) screening modalities have been developed as alternatives to colonoscopy to improve patient compliance and reduce procedural risks. DNA methylation biomarkers are the key high-performing component of non-invasive CRC screening tests based on stool and blood. Recent advances in next-generation sequencing and machine learning have enabled the integration of multi-omics data into non-invasive CRC screening, facilitating the development of diverse biomarker-based tests across multiple sample types.